Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Multiple Myeloma 52Leukemia, Myeloid, Acute 49Lymphoma, Non-Hodgkin 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma 37Leukemia 35Hodgkin Disease 35Myelodysplastic Syndromes 33Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Burkitt Lymphoma 17Lymphoma, Follicular 12Hematologic Neoplasms 12Neoplasms, Plasma Cell 11Congenital Abnormalities 11Lymphoma, B-Cell, Marginal Zone 10Leukemia, Biphenotypic, Acute 9Breast Neoplasms 9Myeloproliferative Disorders 8Lymphoma, Large-Cell, Immunoblastic 8Anemia, Refractory, with Excess of Blasts 8Recurrence 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myelomonocytic, Chronic 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Graft vs Host Disease 6Sarcoma 5

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × Granulocyte Colony-Stimulating Factor × Clear all
NCT00068393 2023-07-07

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Eastern Cooperative Oncology Group

Phase 2 Completed
39 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡